Adventurous investors have long sought out micro-cap stocks, attracted by the profit potential of starting on the bottom floor and rocketing toward blue sky. Biotechnology can add even more power…
We are in the "golden age," of biotech, and Medical Technology Stock Letter Editor John McCamant has innovative ideas on how to glean profits from the renaissance. Investors…
Source: George S. Mack of The Life Sciences Report (5/10/13) http://www.thelifesciencesreport.com/pub/na/15261 Stem cell companies have languished long enough in micro-cap…
In January 2013, The Life Sciences Report debuted its biotech Watchlist, which outlined ideas for investors keyed to catalysts in the drug development process that typically move biotechnology…
Options activity may be used as a starting point for investors looking for companies that are expected to make big moves in the sessions ahead. As long as the share price of a company did not…
Big pharma knows how to market products. But has it lost a step on the drug development side? Is there a better way to incentivize drug development and make money at it? Mark Kessel, co-founder…
Biotech stocks can provide sudden and magnificent returns, but they can be just as unforgiving. How can you decide which biotech stocks are worth investing in then? We looked into it…
No single solution will emerge from the growing realm of stem cell technology and regenerative medicine. Instead, multiple innovations will succeed in a field that promises to forever change the…
Source: George S. Mack of The Life Sciences Report (3/7/13) For the first time in ages, conditions for biotech investment are just right. The capital markets have loosened up, and…
Companies in the biotechnology space are often trade like speculative investments. Speculation for FDA approvals may lead shares higher. Profit-taking often follows after companies gain approvals,…
Load more
